Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Pharma & Biotech

Can OncoNano Medicine’s ON-BOARD platform solve antigen limits in solid tumor drug delivery?

OncoNano Medicine’s AACR 2026 data spotlight ON-BOARD and ONM-421. Read why pH-targeted tumor delivery could reshape oncology development.

Read More
Representative image of acute myeloid leukemia research, illustrating how Orum Therapeutics’ ORM-1153 AACR 2026 data are drawing attention to CD123-targeting degrader-antibody conjugates in AML.
Pharma & Biotech

Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention

Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.

Read More
Representative image of a scientist in a cancer research laboratory, illustrating Onchilles Pharma’s AACR 2026 preclinical update on the NEU-002 systemic solid tumor therapy program.
Pharma & Biotech

How NEU-002 could reshape Onchilles Pharma’s systemic solid tumor strategy after AACR 2026

Onchilles Pharma’s NEU-002 showed systemic anti-tumor activity at AACR 2026. Read what the preclinical data could mean for solid tumor development.

Read More
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More
Representative image of bispecific antibody drug conjugate research as NEOK Bio highlights NEOK001 and NEOK002 at AACR 2026, drawing attention to the next wave of solid tumor ADC development.
Pharma & Biotech

Can bispecific ADCs give NEOK Bio a more credible route into solid tumor drug development?

NEOK Bio unveiled AACR 2026 data for NEOK001 and NEOK002. Read how its bispecific ADC strategy could reshape solid tumor competition.

Read More
Representative image of single-cell tumor analysis and clonal growth profiling, illustrating how SingleCell Biotechnology’s AACR 2026 assay could help link cancer cell behavior to molecular signatures in oncology drug discovery.
Pharma & Biotech

AACR 2026: SingleCell Biotechnology targets oncology’s blind spot with functional single-cell profiling

Read how SingleCell Biotechnology’s AACR 2026 assay could reshape tumor heterogeneity research and oncology drug development.

Read More
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Representative image of a cancer research laboratory and DNA damage analysis, illustrating the translational science behind intoDNA’s sSTRIDE-NER and sSTRIDE-PARP1 assay presentations at AACR 2026.
Medical Devices & Diagnostics

IntoDNA unveils sSTRIDE-NER and sSTRIDE-PARP1 at AACR 2026, can functional DNA repair assays reshape precision oncology?

IntoDNA revealed two novel DNA repair assays at AACR 2026. Read why sSTRIDE-NER and sSTRIDE-PARP1 could matter for oncology biomarker research.

Read More
Representative image of preclinical oncology research linked to Soley Therapeutics’ STX-6398 program, highlighting the growing interest in CKAP2-targeted cancer drug discovery after AACR 2026.
Pharma & Biotech

Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?

Soley Therapeutics unveiled AACR 2026 data for STX-6398. Read why CKAP2 modulation could open a new path in oncology.

Read More
Pharma & Biotech

Akamis Bio AACR 2026 update: what early NG-350A data could mean for organ preservation

Akamis Bio’s NG-350A showed early promise in rectal cancer. Read what the Fortress data could change, and what still needs proving.

Read More